CJC-1295 No-DAC + Ipamorelin Pre-Blend: Practical Tracking

Research suppliers commonly sell CJC-1295 (no-DAC) and ipamorelin as a pre-mixed blend, usually at a 1:1 mass ratio. The appeal is obvious — one reconstitution, one injection, one log entry. The tradeoffs are less obvious and worth thinking about before you commit a tracking protocol to it.

What's in a typical blend

Most commercial research blends list 5 mg CJC-1295 no-DAC + 5 mg ipamorelin per vial. After reconstitution with 2 mL bacteriostatic water, each 0.1 mL delivers 250 mcg of each peptide. The 1:1 ratio reflects the most commonly reported self-experimenter pairing, which uses a GHRH analog to prime the pituitary and a ghrelin mimetic to trigger the release.

Pre-blend vs separate vials

Pre-blend advantages:

• One injection per dose
• Fewer reconstitution errors
• Simpler logging
• Less BAC water and fewer syringes consumed

Separate vial advantages:

• Independent dose adjustment (you can raise ipamorelin without raising CJC, or vice versa)
• You can verify each peptide's effect on its own during a baseline phase
• Stability is per-compound, not lowest-common-denominator
• Easier to swap one component out (e.g., trial GHRP-2 in place of ipamorelin)

Dose precision tradeoffs

The biggest practical issue with blends is that you lose the ability to titrate one peptide without the other. If you notice flushing or headache from the GHRP side, your only lever is to lower both. If your IGF-1 isn't moving, you can't isolate whether the GHRH or the GHRP needs adjustment.

For first-time users with no prior baseline on either peptide alone, this is a real disadvantage for learning what your body does.

What to track daily

• Injection time and total dose (in mcg of each peptide)
• Fasting state at injection
• Acute effects in the first 30 minutes: flush, hunger pang, lightheadedness, tingling
• Time to sleep after evening dose
• Sleep depth

What to track weekly

• Morning weight and waist
• Subjective recovery
• Any water retention or joint discomfort
• Vial age and storage notes (blends can be less stable than single peptides)

Bloodwork worth doing

• Baseline: IGF-1, fasting glucose, HbA1c, prolactin (ipamorelin is selective but the blend output isn't zero)
• IGF-1 at week 6-8
• Repeat fasting glucose at week 8

Realistic expectations

A blend at standard doses produces the same physiological signal as the separate peptides at the same doses. There is no magic from being pre-mixed. People who hope a "blend" is somehow stronger than its parts are misreading the marketing.

Common mistakes

• Assuming the label dose is accurate without verifying supplier testing
• Eating within 90 minutes of injection
• Not logging the blend's expiration date — once reconstituted, 3-4 weeks refrigerated is the commonly cited window
• Switching between brands of blend without re-baselining

A tracking template

In Peptide IA, a blend works best with a single "compound" entry that records both peptides at once, plus a vial-age field. The injection log entry should auto-include both peptide names so downstream analysis still resolves to each compound separately.

When to prefer separate vials

• First time using either peptide
• You suspect a specific side effect from one component
• You want to experiment with a different GHRP (GHRP-2, GHRP-6, hexarelin)
• You're chasing precise IGF-1 targets and need to titrate

Bottom line

A pre-blend is a convenience product. It's a reasonable choice for someone who already knows how they respond to each peptide individually and just wants fewer needles. For learning, separate vials give you cleaner data.

Peptide IA is an educational and self-tracking tool. Nothing in this post is medical advice. Doses mentioned reflect what is commonly reported in research literature — they are not recommendations. Always consult a qualified physician before starting, changing, or stopping any protocol.